OBJECTIVES The study compared, by intravascular ultrasound (IVUS), acute gain (AG) at the site of the pre-procedural minimal lumen area (MLA) achieved by either the Absorb (Abbott Vascular, Santa Clara, California) scaffold or the Xience stent and identified the factors contributing to the acute performance of these devices.
This trend was also observed in the randomized Japanese ABSORB trial (7) (8) (9) . In the ABSORB II randomized trial, pre-procedural and post-procedural documentary IVUS imaging were mandatory and provided a unique opportunity to evaluate the scaffold/stent expansion at the precise site of preprocedural minimal lumen area (MLA) and to relate the degree of expansion to the mechanical performance of both devices, procedural parameters of implantation and tissue composition derived from IVUS analyses (4) . Therefore, the purpose of this study was to investigate the IVUS acute gain at the site of minimal lumen area between the Absorb scaffold and the Xience stent and to identify the factors contributing to the acute performance of these devices. Lesions were treated with routine interventional techniques that included mandatory pre-dilation with a balloon shorter and 0.5 mm smaller in diameter than the study device. The size of stent/scaffold was determined by the target vessel diameter, which was measured by pre-procedural on-line quantitative coronary angiography (QCA) (3,10). All patients enrolled in the ABSORB II trial were treated as follows: 1) a 3.5-mm device was used when both the proximal and distal maximal lumen diameters were within an upper limit of 3.8 mm and a lower limit of 3.0 mm; 2) a 3.0-mm device was used when both the proximal and the distal maximal lumen diameters were within an upper limit of 3.3 mm and a lower limit of 2.5 mm; 3) a 2.5-mm device was used when both the proximal and the distal maximal lumen diameters were within an upper limit of 3.0 mm and a lower limit of 2.25 mm; and 4) scaffold/stent overlap was allowed. Post-dilation with a balloon shorter than the implanted scaffold/stent was performed at the discretion of the operators. Post-procedural IVUS images were obtained at the end of the procedure (post-device implantation or post-dilation). All pullbacks were analyzed offline by an independent core laboratory (Cardialysis BV, Rotterdam, the Netherlands) using commercially available software (QIvus version 2.2, Medis, Leiden, the Netherlands). Sotomi et al.
METHODS
compared with the post-procedural lumen area at the same site. The lower acute gain was defined as the lowest tertile from the whole population.
ANALYSIS OF IVUS AND PROCEDURAL PARAMETERS.
Contour detection was performed by experienced IVUS core laboratory analysts who were unblinded to the device type. IVUS metrics including vessel, stent/ scaffold, and lumen area were measured at 0.5-mm intervals. To identify the lesion factors in the evaluation of acute gain, analysis was also performed using the following parameters: plaque burden, lumen eccentricity, presence of calcium, remodeling index (11) from grayscale IVUS and tissue composition parameters (absolute value and percentage) from IVUS-VH. By IVUS-VH analysis, tissue at the site of preprocedural MLA was divided into 4 basic plaque tissue components: fibrous tissue, fibrofatty tissue, necrotic core, and dense calcium (15) .
In the compliance charts (pressure-diameter relationships) for Absorb and Xience (Prime, Xpedition, and so forth) provided by the manufacturer, the inner Examples of IVUS pullbacks before (A-E) and after procedure (F-I). Vessel and lumen contours were drawn (C) at the site of pre-procedural minimal lumen area (dotted line in longitudinal view [E, F] Sotomi et al.
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maximal inflation pressure and during post-dilation at maximal inflation pressure.
Acute recoil was defined as follows: When a stent/ scaffold delivery balloon was used for stent/scaffold expansion, acute absolute stent/scaffold recoil was Values are mean AE SD or n (%). *7 are missing data. †The polymeric or metallic struts are detected as (pseudo)calcium on IVUS-VH. Figure 2 . Overall, the pre- AG ¼ acute gain; MLA ¼ minimal lumen area.
IVUS-VH

FIGURE 4 Device Expansion of Absorb and Xience
When device expansion was defined as the ratio of post-procedural lumen area at the site of the pre-procedural MLA to the expected inner device area calculated from the largest balloon used during procedure, the Absorb scaffold achieved, on average, 62 AE 12% only of the predicted lumen area, whereas the Xience stent achieved 71 AE 15% (p < 0.001).
MLA ¼ minimal lumen area.
Sotomi et al.
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DEVICE EXPANSION IN MINIMAL LUMEN AREA.
When device expansion (16, 17) PREDICTORS OF LOWER ACUTE GAIN. Lower acute gain (lowest tertile) occurred more frequently in between Absorb and Xience were consistent across these variables (Table 3) . 
IMPACT OF LESION MORPHOLOGY ON LUMEN
ENLARGEMENT. There are conflicting data about the impact of lesion morphology on lumen enlargement. In Xience due to the device mechanical properties (i.e., tensile strength and radial force).
When QCA was performed to assess MLD changes at different phases during the procedure, differences between the 2 arms were already significant at the time of device balloon expansion (Dþ1.50 mm for Xience vs.
Dþ1.23 mm for Absorb; p < 0.01) (Figure 6 ), despite the fact that the expected inner devices' diameters at implantation were similar in both arms. Acute device recoil amounts were comparable between the 2 arms (4). Despite less aggressive post-dilation in the Absorb were excluded from the present study. Thus, our conclusions should not be extrapolated to more complex lesion subsets. Lastly, in the present study, we did not evaluate-due to the small number of the eventsthe relationship between IVUS findings and clinical events such as scaffold thrombosis that is our current concern after implantation of Absorb.
CONCLUSIONS
At the site of pre-procedural MLA, the Absorb scaffold showed lower acute gain than Xience stents. To Sotomi et al.
